Abstract: In various embodiments, a device for determining a condition of an organ of either a human or an animal may be provided. The device may include a first optical source and a second optical source. The device may also include a detector. The device may additionally include a lens system. The device may further include a switching mechanism configured to switch between an optical examination mode and a Raman mode. The lens system during the optical examination mode may be configured to direct a first light emitted from the first optical source. The lens system during the Raman mode may be configured to direct a second light emitted from the second optical source. The lens systems during the Raman mode may be further configured to direct a third light to the detector.

Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.

Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Abstract: According to various embodiments, there is provided an imaging device including a Bessel beam generator configured to provide a Bessel beam; a scanning mirror configured to scan the Bessel beam across a two-dimensional plane; a scan lens configured to receive the Bessel beam from the scanning mirror, a centre of the scan lens being at least substantially a focal length of the scan lens away from the scanning mirror; an illumination tube lens configured to receive the Bessel beam from the scan lens, a centre of the illumination tube lens being at least substantially a sum of the focal length of the scan lens and a focal length of the illumination tube lens away from the centre of the scan lens; an illumination objective lens positioned in direct line-of-sight to a specimen, the illumination objective lens configured to receive the Bessel beam from the illumination tube lens and further configured to illuminate the specimen with the Bessel beam, wherein a centre of the illumination objective lens is at least su

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.

Abstract: Various embodiments relating to a method of controlling the blood pressure of a subject is provided, the method includes generating blood pressure data indicating the blood pressure of the subject, controlling a plurality of pumps to infuse, in dependence on the blood pressure data, drugs into the subject, wherein each of the plurality of pumps is adapted to infuse one out of a plurality of different drugs into the subject, and wherein each of the plurality of different drugs has a particular influence on the blood pressure of the subject, wherein the plurality of pumps is controlled such that, in dependence on the blood pressure data, a mix of drugs is infused into the subject which stabilizes the blood pressure of the subject.

Abstract: A method and apparatus for aligning a two-dimensional eye image with a predefined axis by rotation at a rotation angle are disclosed, the method comprising deriving the rotation angle and a de-noised image, which minimises a cost function comprising (i) a complexity measure of the de-noised image and (ii) magnitude of a noise image obtained by rotating the first image by the rotation angle and subtracting the de-noised image.

Abstract: A sensing device comprising a first array of electrodes encapsulated in a first elastomeric layer; a second array of electrodes encapsulated in a second elastomeric layer; a third elastomeric layer intermediate the first and second elastomeric layer and comprising an array of micro-structures, wherein said electrodes and elastomeric layers are configured such that a displacement of said micro-structures, in response to one or more forces and/or pressures applied to said device, causes a capacitance of said device to vary as a function of said forces and/or pressure applied.

Abstract: A method of producing an artificial neural network capable of predicting the survivability of a patient, including: storing in an electronic database patient health data comprising a plurality of sets of data, each set having at least one of a first parameter relating to heart rate variability data and a second parameter relating to vital sign data, each set further having a third parameter relating to patient survivability; providing a network of nodes interconnected to form an artificial neural network, the nodes comprising a plurality of artificial neurons, each artificial neuron having at least one input with an associated weight; and training the artificial neural network using the patient health data such that the associated weight of the at least one input of each artificial neuron is adjusted in response to respective first, second and third parameters of different sets of data from the patient health data.

Abstract: The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel.

Abstract: Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Abstract: A device 100 for delivering intraocular lens into an incision on an eye of a patient comprises a tubular member 130 defined by a hollow elongate passageway 131, a front 132 and a back through opening 133 of the passageway 131; a secured nozzle 150 having an expanded base 152, which is mounted to the front through opening 132 of the tubular member 130, tapering towards a pointed end 153 fashioned to be inserted into the incision, the secured nozzle 150 enclosing a lumen 154 substantially tapered from the base 152 to the pointed end 153 and aligned with the passageway 131 that the lens is disposed within the lumen 154 to be readily delivered; an elongate probe 110, at least partially housed within the passageway 131, having a bifurcated tip 115 which is configured to telescopically slide out from the pointed end 153 of the secured nozzle 150 pushing the disposed lens into the eye; and a plunger assembly 120 having a shaft 126 inserted into and moveable within the passageway 131 to anteriorly engage with the pro

Abstract: The present disclosure provides a system and method of determining a risk score for triage. In particular, a system is provided for providing an assessment of risk of a cardiac event for a patient, for example an incoming patient to a hospital emergency department complaining of chest pain. In the disclosure, the system includes an input device for measuring physiological data based vital signs parameter of the patient, a twelve-lead electrocardiogram (ECG) device for establishing an ECG obtained from results of the electrocardiography procedure, and determining an ECG parameter and a heart rate variability (HRV) parameter therefrom. An ensemble-based scoring system is further provided, establishing weighted classifier based on past patient data and where the vital signs parameter, the ECG parameter and the HRV parameter are compared to corresponding weighted classifiers to determine a risk score. A corresponding method to determine a risk score for triage is also provided.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: Present invention relates to a method of controlling the discomfort level experienced by a subject. The method comprises receiving a signal from the subject to initiate comfort relief, determining vital sign data of the subject, determining whether the vital sign data fulfills a predetermined criterion, and performing an infusion regime of infusing a comfort relief drug into the subject based on whether the vital sign data fulfills the predetermined criterion.

Abstract: According to embodiments of the present invention, an ocular lens is provided. The ocular lens includes an optical filter configured to change a chromaticity of light impinging on the ocular lens so as to transmit a filtered light to an eye of a viewer, wherein the filtered light comprises a first light having a first peak wavelength in a range of between about 460 nm and about 490 nm and a second peak wavelength in a range of between about 490 nm and about 550 nm.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: A method is proposed for automatically locating the optic disc or the optic cup in an image of the rear of an eye. A portion of the image containing the optic disc or optic cup is divided into sub-regions using a clustering algorithm. Biologically inspired features, and optionally other features, are obtained for each of the sub-regions. An adaptive model uses the features to generate data indicative of whether each sub-region is within or outside the optic disc or optic cup. The result is then smoothed, to form an estimate of the position of the optic disc or optic cup.

Abstract: A method is proposed for identifying an anatomical structure within a spatial-temporal image (i.e. a series of frames captured as respective times). A current frame of spatial-temporal medical image is processed using information from one or more previous and/or subsequent temporal frames, to aid in the segmentation of an object or a region of interest (ROI) in a current frame. The invention is applicable to both two- and three-dimensional spatial-temporal images (i.e., 2D+time or 3D+time), and in particular to cardiac magnetic resonance (CMR images). An initialisation process for this method segments the left ventricle (LV) in a CMR image by a fuzzy c-means (FCM) clustering algorithm which employs a circular shape function as part of the definition of the dissimilarity measure.

Abstract: The present invention provides a method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells from induced pluripotent stem cells. With the method, embryoid bodies are first formed from induced pluripotent stem cells in a non-adherent substrate. The embryoid bodies are then contacted with a serum-free and insulin-free medium comprising a p38-MAPK inhibitor to form aggregates of contracting embryoid bodies. The contracting embryoid body aggregate(s) are then induced to form mesenchymal stem-cell-like cells and aggregates of cardiomyocyte-like stem cells with a medium comprising ?5% serum in a cell-culture treated substrate. The cardiomyocyte-like cells and the mesenchymal stem-cell like cells may be separated to give isolated populations of each cell type. The population of cardiomyocyte-like cells and mesenchymal stem-cell like cells and the isolated population of each cell type may be used for replacing cells.